Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 8

Anakinra, an interleukin-1 receptor antagonist, increases the morphine analgesic effect and decreases morphine tolerance development by modulating oxidative stress and endoplasmic reticulum stress in rats

Pages
2048–2058
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These effects probably occur by the modulation of oxidative stress and ER-stress pathways.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Recent studies have shown that inflammation plays a role in morphine analgesia and tolerance development.
📊
Key Findings & Data:Anakinra is a competitive inhibitor of IL-1 receptors and an antiinflammatory protein regulating IL-1β’s biological activity by avoiding signal transduction.
💡
Conclusion & Impact:These effects probably occur by the modulation of oxidative stress and ER-stress pathways.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Recent studies have shown that inflammation plays a role in morphine analgesia and tolerance development. Anakinra is a competitive inhibitor of IL-1 receptors and an antiinflammatory protein regulating IL-1β’s biological activity by avoiding signal transduction. In this study, we aimed to examine the effects of anakinra on morphine analgesia and tolerance. Materials and methods: In this study, 36 Wistar Albino (230–250 g) male rats were used. Animals were divided into 6 groups: saline (S), 100 mg/kg anakinra (A), 5mg/kg morphine (M), M+A, morphine tolerance (MT), and MT+A. The resulting analgesic effect was measured with hot plate and tail-flick analgesia tests. After the analgesia tests, the dorsal root ganglions (DRG) tissues were removed. Oxidative stress parameters [total antioxidant status (TAS), total oxidant status (TOS)], endoplasmic reticulum (ER) stress, and apoptosis proteins [E74-like factor 2 (elF-2α), activating transcription factor 4 (ATF-4), C/EBP homologous protein (CHOP), caspase-3, and bcl2-associated X protein (bax)] were measured in DRG tissues. Results: Anakinra showed an antinociceptive effect when given alone (P < 0.001). In addition, anakinra increased the analgesic effect of morphine (P < 0.05 to P < 0.001), and also decreased the tolerance to morphine at a significant level (P < 0.05 to P < 0.001). Moreover, it decreased oxidative stress and ER-stress when given as a single-dose morphine and tolerance induction (P < 0.01 to P < 0.001). Furthermore, anakinra decreased apoptosis proteins after tolerance development (P < 0.001). Conclusion: Anakinra has antinociceptive properties, and it increases the analgesic effect of morphine and also prevents tolerance development. These effects probably occur by the modulation of oxidative stress and ER-stress pathways.

🔖

Cite This Article

AVCI, O., TAŞKIRAN, A. Ş. (2022). Anakinra, an interleukin-1 receptor antagonist, increases the morphine analgesic effect and decreases morphine tolerance development by modulating oxidative stress and endoplasmic reticulum stress in rats. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 8, 2048–2058. https://ajindex.com/articles/609747

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Shavit Y, Wolf G, Goshen I, Livshits D, Yirmiya R. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 2005
  2. 115 (1-2): 50-59. doi: 10.1016/j. pain.2005.02.003 2. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. Journal of Neuroscience 2004
  3. 24 (33): 7353-7365. doi: 10.1523/JNEUROSCI.1850-04.2004 3. Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behaviour Immunity 2008
  4. 22 (8): 1178-1189. doi: 10.1016/j.bbi.2008.05.004 4. Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annual Review of Psychology 2000
  5. doi: 10.1146/ annurev.psych.51.1.29 5. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin1β as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988
  6. 334 (6184): 698-700. doi: 10.1038/334698a0 6. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A et al. Interleukin-1 β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001
  7. 410 (6827): 471-475. doi: 10.1038/35068566 7. Cunha JM, Cunha FQ, Poole S, Ferreira SH. Cytokinemediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. British Journal of Pharmacology 2000
  8. 130 (6): 1418-1424. doi: 10.1038/sj.bjp.0703434 8. Wolf G, Yirmiya R, Goshen I, Iverfeldt K, Holmlund L et al. Impairment of interleukin-1 (IL-1) signaling reduces basal pain sensitivity in mice: Genetic, pharmacological and developmental aspects. Pain 2003
  9. 104 (3): 471-480. doi: 10.1016/s0304-3959(03)00067-8 9. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: A systematic review. The Journal of Rheumatology 2009
  10. 36 (6): 1118-1125. doi: 10.3899/jrheum.090074 10. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology 2020
  11. 2 (6): e325-e331. doi: 10.1016/ S2665-9913(20)30127-2 11. Kuyrukluyıldız U, Küpeli İ, Bedir Z, Özmen Ö, Onk D et al. The effect of anakinra on paclitaxel-induced peripheral neuropathic pain in rats. Turkish Journal of Anaesthesiology&Reanimati